Welcome to our dedicated page for Sotera Health Company news (Ticker: SHC), a resource for investors and traders seeking the latest updates and insights on Sotera Health Company stock.
Sotera Health Company (Nasdaq: SHC) is a leading global provider of sterilization, lab testing, and advisory services, primarily serving the medical device, pharmaceutical, and food industries. The company operates through three main segments: Sterigenics, Nordion, and Nelson Labs. Sterigenics offers terminal sterilization and irradiation services, including gamma and electron beam irradiation, and EO processing. Nordion supplies Co-60 and gamma irradiators, which are critical for the gamma sterilization process. Nelson Labs specializes in outsourced microbiological and analytical chemistry testing.
The company is known for its commitment to ensuring the safety and quality of healthcare products through its comprehensive suite of services. Sotera Health’s lab services cover analytical chemistry, medical device testing, pharmaceutical lab testing, and microbiology testing, helping clients identify and mitigate risks. The advisory segment supports clients in navigating regulatory requirements throughout the product lifecycle.
Recently, Sotera Health has achieved significant milestones, including a 6.7% increase in net revenues for its Sterigenics segment in Q3 2023, driven by favorable pricing and currency exchange rates. Nordion reported a 14.3% increase in net revenues, reflecting robust demand for its services.
Despite challenges, the company has shown resilience, evidenced by a 5.8% increase in third-quarter 2023 net revenues to $263 million. However, a net loss of $14 million was reported due to a $35 million legal settlement. Sotera Health’s ongoing projects include expanding its service offerings and enhancing operational efficiencies.
Headquartered in Cleveland, Ohio, the company had $2.3 billion in total debt and $245 million in cash equivalents as of September 30, 2023, reflecting a strong financial position to support its strategic initiatives. The company continues to focus on its mission of 'Safeguarding Global Health®.'
Sotera Health Company (Nasdaq: SHC) reported Q3 2021 net revenues of $226 million, up 13.1% from Q3 2020. Net income rose to $27 million or $0.10 per diluted share, compared to $0.01 million in Q3 2020. Adjusted EBITDA increased 16.1% to $117 million, and Adjusted EPS improved to $0.21. Total debt as of September 30, 2021, was $1.78 billion with a net leverage ratio of 3.6x. The company narrowed its full-year revenue outlook to $920 million - $930 million, reflecting 12% - 14% growth.
Sotera Health Company (Nasdaq: SHC) will release its financial results for Q3 and the first nine months of 2021 on November 10, 2021, prior to market open. A conference call will follow at 9:00 a.m. ET to discuss operational highlights and financial results. Participants from the U.S. and Canada can dial 1-833-303-1211, while international attendees can call 1-918-922-6527. A live webcast will be available on the Company’s investor relations website.
SALT LAKE CITY and OAK BROOK, Ill., September 28, 2021 – Nelson Labs and Sterigenics Germany announced an expansion of their Wiesbaden facility, enhancing microbiological laboratory testing and sterilization capacity. This expansion responds to rising demand from the medical device and pharmaceutical sectors, with the lab now ten times larger, featuring advanced testing capabilities. The upgraded facility will streamline services, reducing outsourcing needs. Sterigenics also increased sterilization capacity, reinforcing its commitment to meet customer demands swiftly and safely.
Sotera Health Company (Nasdaq: SHC) reported Q2 2021 net revenues of $252 million, marking an 18.2% increase year-over-year. Net income rose to $43 million or $0.15 per diluted share from $7 million in Q2 2020. Adjusted EBITDA for the quarter was $135 million, an increase of 17.6%. The company enhanced its full-year revenue outlook to $920 million - $940 million and adjusted EBITDA outlook to $475 million - $490 million. As of June 30, 2021, total debt stood at $1.9 billion, with an improved net leverage ratio of 3.8x.
Sotera Health Company (Nasdaq: SHC) will release its second quarter and six months financial results on August 12, 2021, before market open. This announcement includes an upcoming conference call at 9:00 a.m. Eastern Time for detailed discussion on operating highlights and financial metrics. Investors can dial in or access a live webcast through the company's Investor Relations webpage. Sotera Health focuses on providing vital sterilization solutions and lab testing services to the healthcare sector, aiming to safeguard global health.
Sotera Health Company (Nasdaq: SHC) reported Q1 2021 net revenues of $212 million, up 13% from Q1 2020. The company posted a net income of $11 million or $0.04 per diluted share, reversing the $2 million loss in the same quarter last year. Adjusted EBITDA rose 15% to $105 million, and Adjusted EPS increased 80% to $0.18. The total debt stood at $1.87 billion, with a net leverage ratio of 4.1x. Sotera Health reaffirmed its 2021 outlook, expecting net revenues between $890 million and $920 million.
Sotera Health Company (Nasdaq: SHC) will release its financial results for Q1 2021 on May 13, 2021, before market open. A conference call is scheduled for 9:00 a.m. ET to discuss operating highlights and results. Interested participants can join by dialing 1-833-303-1211 (US/Canada) or 1-918-922-6527 (international). Sotera Health will also present at the RBC Capital Markets Global Healthcare Conference on May 18, 2021, at 8:00 a.m. ET. The company is recognized for its end-to-end sterilization solutions and lab testing services, supporting healthcare globally.
Sotera Health Company (Nasdaq: SHC) announced the pricing of its secondary offering of 25,000,000 shares at $27.00 per share, with selling stockholders, including affiliates of Warburg Pincus LLC and GTCR, LLC. The offering will not raise funds for the company, which will not receive any proceeds. A 30-day option for underwriters to purchase an additional 3,750,000 shares is included. The offering closes on March 22, 2021, subject to conditions. Key underwriters include J.P. Morgan, Credit Suisse, and Goldman Sachs.
Sotera Health Company announced a secondary offering of 25,000,000 shares of its common stock, aimed exclusively at selling stockholders, including affiliates of Warburg Pincus LLC and GTCR, LLC. The offering allows underwriters a 30-day option to purchase an additional 3,750,000 shares. Notably, Sotera will not receive any proceeds from this offering. The company is also seeking an amendment to its credit agreement to improve terms and extend maturity on its undrawn revolving credit facility, although success is uncertain due to varying market conditions.
Sterigenics S.A.S., a Sotera Health subsidiary, is expanding its ethylene oxide sterilization facility in Rantigny, France, to enhance sterilization capacity and capability. This expansion addresses increased local and regional demand for contract sterilization services in the healthcare sector. The facility will now include a 32-pallet chamber, improving throughput and flexibility for customers. This development follows Sterigenics' recent acquisition of Iotron Industries, further diversifying sterilization technologies and enhancing global service offerings.
FAQ
What is the current stock price of Sotera Health Company (SHC)?
What is the market cap of Sotera Health Company (SHC)?
What services does Sotera Health Company offer?
What are the main segments of Sotera Health?
How did Sotera Health perform in the third quarter of 2023?
What are the key components of the gamma sterilization process provided by Nordion?
What financial condition is Sotera Health in as of September 30, 2023?
What recent achievements has Sotera Health made?
Where is Sotera Health headquartered?
What is the company’s mission?
What are Sotera Health’s advisory services focused on?
What recent financial results did Sotera Health announce?
